Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 3
2011 4
2012 1
2013 4
2014 2
2015 10
2016 7
2017 7
2018 6
2019 18
2020 15
Text availability
Article attribute
Article type
Publication date

Search Results

74 results
Results by year
Filters applied: . Clear all
Page 1
Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries.
Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, Germini F; Data and Demographics Committee of the World Federation of Hemophilia. Iorio A, et al. Ann Intern Med. 2019 Oct 15;171(8):540-546. doi: 10.7326/M19-1208. Epub 2019 Sep 10. Ann Intern Med. 2019. PMID: 31499529
RESULTS: Prevalence (per 100 000 males) is 17.1 cases for all severities of hemophilia A, 6.0 cases for severe hemophilia A, 3.8 cases for all severities of hemophilia B, and 1.1 cases for severe hemophilia B. ...The life expectancy disadvantage for hi …
RESULTS: Prevalence (per 100 000 males) is 17.1 cases for all severities of hemophilia A, 6.0 cases for severe hemophilia A, 3 …
Emicizumab and thrombosis: The story so far.
Makris M, Iorio A, Lenting PJ. Makris M, et al. Among authors: iorio a. J Thromb Haemost. 2019 Aug;17(8):1269-1272. doi: 10.1111/jth.14556. J Thromb Haemost. 2019. PMID: 31368220 Free article. No abstract available.
Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Shah A, Solms A, Wiegmann S, Ahsman M, Berntorp E, Tiede A, Iorio A, Mancuso ME, Zhivkov T, Lissitchkov T. Shah A, et al. Among authors: iorio a. Ann Hematol. 2019 Sep;98(9):2035-2044. doi: 10.1007/s00277-019-03747-2. Epub 2019 Jun 24. Ann Hematol. 2019. PMID: 31236667 Free PMC article. Clinical Trial.
BAY 94-9027 is an extended-half-life, recombinant factor VIII (rFVIII) product conjugated with a 60-kDa branched polyethylene glycol (PEG) molecule indicated for use in previously treated patients (aged ≥ 12 years) with hemophilia A. This randomized, open-label, two-way cr …
BAY 94-9027 is an extended-half-life, recombinant factor VIII (rFVIII) product conjugated with a 60-kDa branched polyethylene glycol (PEG) m …
Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
Carcao MD, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, Hossain T, Rand ML, Brown C, Edginton AN, Lillicrap D, Iorio A, Blanchette VS. Carcao MD, et al. Among authors: iorio a. J Thromb Haemost. 2019 Jul;17(7):1085-1096. doi: 10.1111/jth.14469. Epub 2019 Jun 2. J Thromb Haemost. 2019. PMID: 31038793
Recently, boys (ages 12-18 years) with hemophilia A in Canada were required to switch from Eloctate to Adynovate. OBJECTIVES: Compare the PK profiles of Eloctate vs Adynovate in the same boys. ...
Recently, boys (ages 12-18 years) with hemophilia A in Canada were required to switch from Eloctate to Adynovate. OBJECTIVES: Compare …
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.
Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M; Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG). Iorio A, et al. Thromb Haemost. 2017 Jun 2;117(6):1023-1030. doi: 10.1160/TH16-12-0942. Epub 2017 Mar 30. Thromb Haemost. 2017. PMID: 28357444 Review.
The prophylactic administration of factor IX (FIX) is considered the most effective treatment for haemophilia B. The inter-individual variability and complexity of the pharmacokinetics (PK) of FIX, and the rarity of the disease have hampered identification of an optimal tr …
The prophylactic administration of factor IX (FIX) is considered the most effective treatment for haemophilia B. The inter-individual …
Switching patients in the age of long-acting recombinant products?
Escobar M, Santagostino E, Mancuso ME, Coppens M, Balasa V, Taylor JA, Iorio A, Negrier C. Escobar M, et al. Among authors: iorio a. Expert Rev Hematol. 2019;12(sup1):1-13. doi: 10.1080/17474086.2018.1564032. Expert Rev Hematol. 2019. PMID: 31282771 Review.
Introduction: Prophylaxis with factor replacement therapy is the gold standard for the treatment of hemophilia, but this often requires frequent infusions. ...Areas covered: This is an overview of information presented at two symposia held at the World Federation of Hem
Introduction: Prophylaxis with factor replacement therapy is the gold standard for the treatment of hemophilia, but this often requir …
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations.
Iorio A, Edginton AN, Blanchette V, Blatny J, Boban A, Cnossen M, Collins P, Croteau SE, Fischer K, Hart DP, Ito S, Korth-Bradley J, Lethagen S, Lillicrap D, Makris M, Mathôt R, Morfini M, Neufeld EJ, Spears J. Iorio A, et al. Res Pract Thromb Haemost. 2018 May 20;2(3):535-548. doi: 10.1002/rth2.12106. eCollection 2018 Jul. Res Pract Thromb Haemost. 2018. PMID: 30046759 Free PMC article. Review.
OBJECTIVES: In a separate document, we have provided specific guidance on performing individual pharmacokinetic (PK) studies using limited samples in persons with hemophilia with the goal to optimize prophylaxis with clotting factor concentrates. This paper, intended for c …
OBJECTIVES: In a separate document, we have provided specific guidance on performing individual pharmacokinetic (PK) studies using limited s …
Hemophilia trials in the twenty-first century: Defining patient important outcomes.
Konkle BA, Skinner M, Iorio A. Konkle BA, et al. Among authors: iorio a. Res Pract Thromb Haemost. 2019 Mar 12;3(2):184-192. doi: 10.1002/rth2.12195. eCollection 2019 Apr. Res Pract Thromb Haemost. 2019. PMID: 31011702 Free PMC article. Review.
Treatment for hemophilia has advanced dramatically over the past 5 decades. Success of prophylactic therapy in preventing bleeding and decreasing associated complications has established a new standard of care. ...This manuscript reviews strengths and limitations of outcom …
Treatment for hemophilia has advanced dramatically over the past 5 decades. Success of prophylactic therapy in preventing bleeding an …
Joint Bleeding Tendencies in Adult Patients With Hemophilia: It's Not All Pharmacokinetics.
Zhou JY, Barnes RFW, Foster G, Iorio A, Cramer TJ, von Drygalski A. Zhou JY, et al. Among authors: iorio a. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619862052. doi: 10.1177/1076029619862052. Clin Appl Thromb Hemost. 2019. PMID: 31298044 Free PMC article.
Hemophilic arthropathy from joint bleeding remains a complication with major morbidity in the increasingly aging patients with hemophilia. ...Here, we prospectively followed a cohort of adult patients with hemophilia A and B (n = 26) and arthropathic joints on vario …
Hemophilic arthropathy from joint bleeding remains a complication with major morbidity in the increasingly aging patients with hemophilia
Using pharmacokinetics to individualize hemophilia therapy.
Iorio A. Iorio A. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):595-604. doi: 10.1182/asheducation-2017.1.595. Hematology Am Soc Hematol Educ Program. 2017. PMID: 29222309 Free PMC article. Review.
Prevention and treatment of bleeding in hemophilia requires that plasma clotting factor activity of the replaced factor exceeds a defined target level. ...Population pharmacokinetics provide an important theoretical and practical contribution to tailoring the treatment of …
Prevention and treatment of bleeding in hemophilia requires that plasma clotting factor activity of the replaced factor exceeds a def …
74 results
Jump to page
Feedback